Valneva (VALN) Projected to Post Earnings on Monday

Valneva (NASDAQ:VALN) is anticipated to issue its Q4 2025 TU results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $50.6630 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 TU earning overview page for the latest details on the call scheduled for Thursday, February 19, 2026 at 1:00 AM ET.

Valneva Trading Down 5.3%

NASDAQ VALN opened at $10.52 on Monday. Valneva has a 12 month low of $5.43 and a 12 month high of $12.25. The company has a current ratio of 1.78, a quick ratio of 1.36 and a debt-to-equity ratio of 0.72. The stock’s fifty day moving average price is $9.97 and its 200-day moving average price is $9.59. The stock has a market cap of $905.88 million, a P/E ratio of -7.31 and a beta of 1.79.

Hedge Funds Weigh In On Valneva

A number of institutional investors have recently bought and sold shares of the stock. Marex Group plc purchased a new position in shares of Valneva during the 2nd quarter valued at $64,000. XTX Topco Ltd purchased a new stake in Valneva in the 4th quarter worth $94,000. Finally, JPMorgan Chase & Co. purchased a new stake in Valneva in the 3rd quarter worth $124,000. 11.39% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut shares of Valneva from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.